Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Guardian Pharmacy Services (GRDN) over the last 3 years, with Q3 2025 value amounting to -$1.5 million.

  • Guardian Pharmacy Services' Cash from Financing Activities fell 10341.21% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.6 million, marking a year-over-year decrease of 58081.56%. This contributed to the annual value of -$23.6 million for FY2024, which is 5868.64% up from last year.
  • Latest data reveals that Guardian Pharmacy Services reported Cash from Financing Activities of -$1.5 million as of Q3 2025, which was down 10341.21% from -$2.1 million recorded in Q2 2025.
  • In the past 5 years, Guardian Pharmacy Services' Cash from Financing Activities ranged from a high of $44.9 million in Q3 2024 and a low of -$48.3 million during Q4 2024
  • Over the past 3 years, Guardian Pharmacy Services' median Cash from Financing Activities value was -$4.1 million (recorded in 2024), while the average stood at -$5.4 million.
  • In the last 5 years, Guardian Pharmacy Services' Cash from Financing Activities tumbled by 26361.86% in 2024 and then soared by 8558.47% in 2025.
  • Guardian Pharmacy Services' Cash from Financing Activities (Quarter) stood at -$13.3 million in 2023, then plummeted by 263.62% to -$48.3 million in 2024, then skyrocketed by 96.82% to -$1.5 million in 2025.
  • Its last three reported values are -$1.5 million in Q3 2025, -$2.1 million for Q2 2025, and -$2.7 million during Q1 2025.